Effect of Baseline Characteristics on the Efficacy and Safety of Once-Daily Darunavir/ Ritonavir in HIV-1–Infected, Treatment-Naïve ARTEMIS Patients at Week 96

REFERENCES

• Clumeck N, Pozniak A, Raffi F, et al. European AIDS Clini-cal Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008;9: 65–71.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adoles-cents. 2009. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1,2009; 1-161. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdo-lescentGL.pdf. Accessed December 3,2010.
   Google Scholar
• Hammer SM, Eron JJ Jr, Reiss P, et al. Treatment for Adult HIV infection. 2008 recommendations of the International AIDS Society-USA Panel. JAMA. 2008;300:555–570.
   PubMed Web of Science ®Google Scholar
• Lennox JL, DeJesus E, Lazzarin A, et al. Safety and effi-cacy of raltegravir-based versus efavirenz-based com-bination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised con-trolled trial. Lancet. 2009;374:796–806.
   PubMed Web of Science ®Google Scholar
• Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected patients at week 48. AIDS. 2008;22:1389–1397.
   PubMed Web of Science ®Google Scholar
• Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs lopinavir/ritonavir in treatment-naïve, HIV-1-infected patients: 96-week analysis of ARTEMIS. AIDS. 2009;23:1679–1688.
   PubMed Web of Science ®Google Scholar
• Brarias F, Berenguer J, Sanchez-Conde M, et al. The eldest of older adults living with HIV: response and adher-ence to highly active antiretroviral therapy. Am J Med. 2008;121:820–824.
   PubMed Web of Science ®Google Scholar
• Kumar PN, Rodriguez-French A, Thompson MA, et al. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfanavir, and lamivudine/stavudine/nefanavir on lipids, metabolic parameters and efficacy in antiretro-viral-naïve patients: effect of sex and ethnicity. HIV Med. 2006;7:85–98.
   PubMed Web of Science ®Google Scholar
• Tedaldi EM, Abalson J, Thomas AJ, et al. Ethnicity, race and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST study). J Aquir Immune Defic Syndr. 2008;47:441–448.
   PubMed Web of Science ®Google Scholar
• Bica I, McGovern B, Dahr R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32: 492–497.
   PubMed Web of Science ®Google Scholar
• Lohse N, Hansen AB, Gerstoft J, et al. Improved survival in HIV-infected persons: consequences and perspectives. J Antimicrob Chemother 2007;60:461–463.
   PubMed Web of Science ®Google Scholar
• Martin-Carbonero L, Soriano V, Valencia E, et al. Increas-ing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroyituses. 2001;17:1467–1471.
   PubMed Web of Science ®Google Scholar
• Andrade-Villanueva J, Herrera G, Chiliade P, et al. ARTEMIS: Week 48 safety and efficacy of darunavir/r by gender, age and race. In: Program and abstracts of the 17th International AIDS Conference; 2008. [Abstract TUPE0064]
   Google Scholar
• Prezista (darunavir). Full US prescribing information. Tibotec, Inc. 2009. http://www.prezista.com/prezista/documents/us_package_insert.pdf. Accessed December, 32010.
   Google Scholar
• Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. AIDS Clinical Trials Group Network. December 2004. https://actgnetwork.org/sci-ence-mission/guidelines/antiretoviral-treatment. Accessed December 3,2010.
   Google Scholar
• AIDS epidemic update: December 2006. UNAIDS (Joint United Nations Program on HIV/AIDS). December 2006. http://www.unaids.org/en/KnowledgeCentre/HlVDatalEpiUpdate/EpiUpdArchive/2006/Default.asp. Accessed December 3, 2010.
   Google Scholar
• Greenbaum AH, Wilson LE, Keruly JC, et al. Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. AIDS. 2008;22:2331–2339.
   PubMed Web of Science ®Google Scholar
• Hartzell JD, Spooner K, Howard R, et al. Race and mental health diagnosis are risk factors for highly active antiretroviral therapy failure in a military cohort despite equal access to care. J Aquir Immune Defic Syndr 2007;44:411–416.
   PubMed Web of Science ®Google Scholar
• US prescribing information. Invirase (saquinavir mesylate). http://www.rocheusa.com/products/invirase. Accessed December 3, 2010.
   Google Scholar
• Smith KY, Kumar PN, Patel P, et al. Differences in viro-logic response among African-Americans and Females regardless of therapy in the HEAT study. In: Program and abstracts of the 5th Conference of HIV Pathogenesis, Treatment and Prevention; 2009. [Abstract MOPE033]
   Google Scholar
• Jang Y-R, Zhou J, Chuang S-Y, et al. Impact of HBV and HCV coinfection on the outcomes of antiretroviral treatment (ART) and disease progression in HIV-infected patients in Taiwan. In: Program and abstracts of the 5th Conference of HIV Pathogenesis, Treatment and Prevention; 2009. [Abstract WEPEB224]
   Google Scholar
• Gulick R, Ribaudao H, Shikuma C, et al. Zidovudine/lami-vudine/abacavir vs zidovudine/lamivudine + efavirenz vs zidovudin/lamivudine/abacavir + efavirenz for initial HIV therapy. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005. [Abstract H-416a]
   Google Scholar
• da Silva B, King M, Cernohous P, et al. Lopinavir/ritonavir (LPV/r) safety, tolerability and efficacy in HIV patients co-infected with hepatitis C and/or B: review of clinical trials. In: Program and abstracts of the 15th International AIDS Conference; 2004. [Abstract M0PeB3281]
   Google Scholar
• Dieterich D, Fischl M, Speulveda G. The safety/efficacy of protease inhibitors in hepatitis C (HCV) coinfected patients. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003. [Abstract H–831]
   Google Scholar
• Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex dif-ferences in nevirapine rash. Clin Infect Dis. 2001;32: 124–129.
   PubMed Web of Science ®Google Scholar
• Vitezica ZG, Milpied B, Lonjou C, et al. HLA-DRB1"01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS. 2008;22:540–541.
   PubMed Web of Science ®Google Scholar
• Dore G. Antiretroviral therapy-related hepatotoxicity: predictors and clinical management. J HIV Ther. 2003;8: 96–100.
   PubMedGoogle Scholar
• SulkowskiM S, Mehta SH, Chaisson RE, et al. Hepatotox-icity associated with protease inhibitor-based antiretro-viral regimens with or without concurrent ritonavir. AIDS. 2004;18:2277–2284.
   PubMed Web of Science ®Google Scholar